Charles Schwab Investment Management Inc Design Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 250,949 shares of DSGN stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
250,949
Previous 258,375
2.87%
Holding current value
$1.25 Million
Previous $997,000
15.25%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding DSGN
# of Institutions
96Shares Held
33.6MCall Options Held
13KPut Options Held
0-
Sr One Capital Management, LP6.53MShares$32.5 Million7.89% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$21 Million1.83% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$11.5 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$9.73 Million0.35% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.81MShares$9 Million0.01% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $278M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...